April 8, 2024 in KVA1213 Publications

Interim results of the ongoing phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors

Thierra Guillaudeux, PhD, Chief Scientific Officer, Kineta Inc American Association of Cancer Research Annual Meeting | April 8, 2024

Read More
April 8, 2024 in Kineta Press Release

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

  Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with ...

Read More